Medicine
Subvenite 25 mg tablet
Subvenite 25 mg tablet is a prescription medicine containing Lamotrigine for oral use, marketed by OWP Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25° C (68° to 77° F), excursions permitted to 15° to 30° C…
Key facts
- Active ingredient (INN)
- Lamotrigine
- Brand
- Subvenite
- Strength
- 25 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 6600 tablets
- Marketing authorisation holder
- OWP Pharmaceuticals
- Manufacturer
- OWP Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25° C (68° to 77° F), excursions permitted to 15° to 30° C (59° to 86° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N03AX09 Lamotrigine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 March 2018
- Identifiers
- RxCUI 198427, 198428, 198429 +7DailyMed set ID 7ad18b68-ba16-4810-9c3e-27fa970454e8NDC 69102-301Application ANDA078947
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 69102-301-01 | OWP Pharmaceuticals | 10 March 2018 |
| 6600 tablet in 1 bottle | 69102-301-02 | OWP Pharmaceuticals | 10 March 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 27 December 1994 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lamotrigine 25 mg tablet.
Other strengths and forms of Lamotrigine
Clinical summary
Lamotrigine is an anti-epileptic agent indicated for epilepsy—adjunctive therapy in patients aged 2 years and older, among other approved uses. It is available as tablets, extended-release tablets and orally disintegrating tablets. MedsAcross supplies Lamotrigine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LamotrigineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LAMICTAL prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
Need Subvenite 25 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.